The effects of averaging on accuracy of IVIVC model predictions

Journal of Pharmaceutical Sciences

Volumn 98, Issue 10, 2009, Pages 3829-3838

  Gaynor, Clare ^a   Dunne, Adrian ^a   Davis, John ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Analysis; Controlled release; Dissolution rate; In vitro in vivo correlations (IVIVC); Mathematical model; Population pharmacokinetics

Indexed keywords

ARTICLE; COMPUTER SIMULATION; CONTROLLED RELEASE FORMULATION; DISSOLUTION; DRUG ABSORPTION; DRUG EFFECT; DRUG ELIMINATION; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL MODEL;

EID: 70349244758     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21662     Document Type: Article

References (15)

1. Food and Drug Administration. 1997. Guidance for Industry: Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations.
2. Madden FN, Godfrey KR, Chappell MJ, Hovorka R, Bates RA. 1996. A comparison of six deconvolution techniques. J Pharmacokinet Biopharm 24:283-299.
3. Dunne A. 2007. Approaches to developing in vitroin vivo correlation models. In: Chilukuri DM, Sunkara G, Young D, editors. Pharmaceutical product development in vitro-in vivo correlation. 47-70.
4. Farrell C, Hayes S. 2007. IVIVC for oral drug delivery: Immediate and extended release dosage forms. In: Chilukuri DM, Sunkara G, Young D, editors. Pharmaceutical product development in vitro-in vivo correlation. New York: Taylor and Francis. 47-70.
5. Polli JE, Crison JR, Amidon GL. 1996. Novel approach to the analysis of in vitro-in vivo relationships. J Pharm Sci 85:753-760. (Pubitemid 26234682)
6. Uppoor VRS. 2001. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Contr Release 72:127-132.
7. Sirisuth N, Augsburger LL, Eddington ND. 2002. Development and validation of a non-linear IVIVC model for a diltiazem extended release formulation. Biopharm Drug Dispos 23:1-8. (Pubitemid 34256937)
8. Johnson NL, Kotz S, Balakrishnan N. 1972. [Continuous univariate distributions.Vol. 1, Wiley & Sons, New York. (1994)] Pharm Pharmacol 24:979-981.
9. Beal SL, Sheiner LB. 1992. NONMEM user's guides,NONMEMproject group. University of California. San Francisco.
10. Hovorka R, Chappell MJ, Godfrey KR, Madden FN, Rouse MK, Soons PA. 1998. CODE: A deconvolution program implementing a regularization method of deconvolution constrained to non-negative values. Description and pilot evaluation. Biopharm Drug Dispos 19:39-53.
11. Dunne A, Gaynor C, Davis J. 2005. Deconvolution based approach for level a in vivo-in vitro correlation modelling: Statistical considerations. Clin Res Regul Aff 22:1-14. (Pubitemid 40756840)
12. Gaynor C, Dunne A, Davis J. 2008. A comparison of the prediction accuracy of two IVIVC modelling techniques. J Pharm Sci 97:3422-3432.
13. O'Hara T, Hayes S, Davis J, Devane J, Smart T, Dunne A. 2001. In vivo-in vitro correlation (IVIVC) modeling incorporating a convolution step. J Pharmacokinet Pharmacodyn 28:277-298.
14. Rossenu S, Gaynor C, Vermeulen A, Cleton A, Dunne A. A nonlinear mixed effects ivivc model for multi-release drug delivery systems. J Pharmacokinet Pharmacodyn 35:423-441.
15. Cotton WD. 1999. Special problems in imaging - Synthesis imaging in radio astronomy II. In: TaylorGB, CarilliCL, Perley RA, editors. ASP conference series. Vol.180, pp. 357-370.